Tempus projects $1.60B-$1.605B 2026 revenue while targeting $65M adjusted EBITDA
FROM THE WIRE · SEEKINGALPHA.COM
Tempus AI Q3 2026 earnings: higher guidance, EBITDA inflection, BMS data deal, and 2027 oncology pricing tailwinds.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishHigher guidance and the BMS collaboration are positives for this AI oncology company's stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Tempus projects 2026 revenue between $1.60 billion and $1.605 billion.
- 02It targets $65 million in adjusted EBITDA.
- 03Third quarter results include a data deal with BMS.
- 04Oncology pricing tailwinds are expected in 2027.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets